Jazz inks Redx pact to secure 2 targeted cancer therapies

Jazz Pharmaceuticals has struck a deal to source two targeted cancer therapies from Redx Pharma. Redx will pocket $10 million upfront, with more to follow, in return for developing candidates against two targets on the Ras/Raf/MAP kinase (MAPK) pathway.